Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-6362 (Electronic) Linking ISSN: 14786354 NLM ISO Abbreviation: Arthritis Res Ther Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, 2003-
    • Subject Terms:
      Antigens, Neoplasm*/urine ; Biomarkers, Tumor*/urine ; Kidney*/pathology ; Lupus Nephritis*/pathology; Biomarkers/metabolism ; Cross-Sectional Studies ; Galectin 3 ; Humans
    • Abstract:
      Objective: There is an urgent need to identify novel biomarkers of LN to reflect renal histological changes. This study aims to investigate urinary G3BP levels in LN patients and their association with renal disease activity both clinically and pathologically.
      Methods: This is a cross-sectional study. A total of 119 lupus nephritis patients were recruited. Thirty patients with chronic kidney diseases (CKD) and 27 healthy volunteers were also recruited as controls. Urinary G3BP was tested by ELISA. Renal histopathology was reviewed by an experienced renal pathologist. Other clinical variables were collected through chart review.
      Results: The levels of uG3BP were significantly increased in active LN patients compared to those in inactive LN (p<0.001), CKD patients (p=0.01), and healthy controls (p<0.001). ROC analysis indicated a good discrimination ability of uG3BP to differentiate active LN from CKD patients (AUC=0.7), inactive LN (AUC=0.76), or healthy controls (AUC=0.87). uG3BP was positively correlated with SLEDAI (ρ=0.352, p<0.001), rSLEDAI (ρ=0.302, p<0.001), and SLICC RAS (ρ=0.465, p<0.001), indicating a role as a biomarker of disease activity. It also correlated with clinical parameters, including 24-h urine protein, ESR, and serum C3 levels. In patients with 24-h urine protein > 3.0 g/24h, uG3BP levels were higher in proliferative LN than in membranous LN (p=0.04). They could discriminate the two pathogenic types of LN (AUC=0.72), and they also positively correlated with AI (ρ=0.389, p=0.008) and scores of hyaline deposits (ρ=0.418, p=0.006). While in patients with 24-h urine protein ≤ 3.0 g/24h, uG3BP levels were not significantly different between proliferative and membranous LN, and there was no apparent relationship between uG3BP levels with AI or with scores of hyaline deposits, but they correlated positively with scores of cellular/fibrocellular crescents (ρ=0.328, p=0.04).
      Conclusion: uG3BP is a non-invasive biomarker for clinically and histologically reflecting disease activity. It is associated with active histological changes and can be used as a surrogate biomarker when the renal biopsy is impractical.
      (© 2022. The Author(s).)
    • References:
      Lupus Sci Med. 2014 Nov 19;1(1):e000026. (PMID: 25452879)
      Lupus. 2019 Mar;28(3):265-272. (PMID: 30712490)
      Lupus. 2000;9(8):614-21. (PMID: 11035437)
      Arthritis Rheum. 2008 Jun;58(6):1784-8. (PMID: 18512819)
      Nephrol Dial Transplant. 2017 Aug 01;32(8):1338-1344. (PMID: 26250434)
      Cancer Res. 2002 May 1;62(9):2535-9. (PMID: 11980646)
      J Biol Chem. 1993 Jul 5;268(19):14245-9. (PMID: 8390986)
      Kidney Int. 2018 Apr;93(4):789-796. (PMID: 29459092)
      Rheumatology (Oxford). 2020 Nov 1;59(11):3424-3434. (PMID: 32353879)
      Rheumatology (Oxford). 2011 Aug;50(8):1424-30. (PMID: 21415024)
      Immunol Invest. 2020 Feb;49(1-2):15-31. (PMID: 31298049)
      Clin Proteomics. 2017 Apr 8;14:11. (PMID: 28405179)
      Ren Fail. 2020 Nov;42(1):166-172. (PMID: 32054387)
      Ann Rheum Dis. 2020 Oct;79(10):1349-1361. (PMID: 32651195)
      Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5. (PMID: 12604793)
      Lupus. 2008 Aug;17(8):720-6. (PMID: 18625649)
      J Immunol. 2015 Aug 15;195(4):1858-67. (PMID: 26136428)
      Clin Nephrol. 1995 May;43(5):288-96. (PMID: 7543387)
      Clin Exp Rheumatol. 2007 Jul-Aug;25(4 Suppl 45):S41-5. (PMID: 17949550)
      Arthritis Res Ther. 2012 Jul 13;14(4):R164. (PMID: 22788914)
      J Rheumatol. 1993 May;20(5):809-14. (PMID: 7687701)
      Arthritis Rheum. 2013 Oct;65(10):2680-90. (PMID: 23817959)
      Lupus. 2015 Oct;24(11):1150-60. (PMID: 25837289)
      Clin Exp Immunol. 1994 Sep;97(3):439-44. (PMID: 7521807)
      J Rheumatol. 2002 Feb;29(2):288-91. (PMID: 11838846)
      Kidney Int. 2018 Oct;94(4):788-794. (PMID: 30045812)
      J Autoimmun. 2016 Nov;74:27-40. (PMID: 27349351)
      Nat Rev Dis Primers. 2020 Jan 23;6(1):7. (PMID: 31974366)
      Rheumatology (Oxford). 2020 Sep 1;59(9):2237-2249. (PMID: 31722419)
      J Am Chem Soc. 2015 Aug 5;137(30):9685-93. (PMID: 26168351)
      Br J Rheumatol. 1994 Dec;33(12):1112-6. (PMID: 7528085)
      Lupus. 2018 Apr;27(5):771-779. (PMID: 29233037)
      Arthritis Res Ther. 2020 May 27;22(1):122. (PMID: 32460901)
      Nat Immunol. 2019 Jul;20(7):902-914. (PMID: 31209404)
      Clin Investig. 1994 Oct;72(10):762-8. (PMID: 7532481)
      Adv Chronic Kidney Dis. 2019 Sep;26(5):360-368. (PMID: 31733720)
      Kidney Int. 2020 Jan;97(1):156-162. (PMID: 31685314)
    • Contributed Indexing:
      Keywords: Activity index; Biomarker; Galectin-3 binding protein; Lupus nephritis; Renal biopsy; Systemic lupus erythematosus
    • Accession Number:
      0 (Antigens, Neoplasm)
      0 (Biomarkers)
      0 (Biomarkers, Tumor)
      0 (Galectin 3)
      0 (LGALS3BP protein, human)
    • Publication Date:
      Date Created: 20220329 Date Completed: 20220404 Latest Revision: 20220531
    • Publication Date:
      20240104
    • Accession Number:
      PMC8962213
    • Accession Number:
      10.1186/s13075-022-02763-4
    • Accession Number:
      35346341